Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 4/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564865 | 0.91 | VDR (0.38) | VDRHDAC3HDAC6FFAR4FFAR1 | |
| SCHEMBL5569105 | 0.91 | VDR (0.46) | VDRHDAC3HDAC6ARHDAC1 | |
| SCHEMBL5565327 | 0.89 | VDR (0.38) | VDRHDAC3HDAC6ARFFAR4 | |
| SCHEMBL5569602 | 0.87 | VDR (0.39) | VDRHDAC3HDAC6AR | |
| SCHEMBL5569478 | 0.85 | FFAR4 (0.39) | VDRHDAC3HDAC6ARFFAR4 | |
| SCHEMBL5566496 | 0.84 | VDR (0.38) | VDR | |
| SCHEMBL5569388 | 0.83 | VDR (0.37) | VDRHDAC3HDAC6ARHDAC1 | |
| SCHEMBL5569440 | 0.82 | VDR (0.57) | VDRHDAC3HDAC6ARHDAC1 | |
| SCHEMBL5569570 | 0.82 | VDR (0.36) | VDRHDAC3HDAC6FFAR4FFAR1 | |
| SCHEMBL5564850 | 0.81 | VDR (0.45) | VDRHDAC3HDAC6ARHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | claimed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | claimed |
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885HDAC3 2976/4885HDAC6 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.